Rainbow Coral Corp. is well positioned to capitalize on the revolution in medicine being spurred on by 3D printing technology, a new 3D bioprinting system developed by RBCC's joint venture partner, Nano3D Biosciences. The BiO Assay uses magnetism to assemble cells in 3D and into conditions that closely mimic those found in vivo, giving drug makers functional preclinical human tissues far more useful than any animal or test tube models.

And with better testing results will come bigger profits for drug companies. The BiO Assay represents a revolution in pharmaceutical research, offering better and faster results than have previously been possible. RBCC formed a biotech subsidiary, Rainbow Biosciences, to market and develop new medical and research technology innovations to compete alongside companies such as Biogen Idec Inc., Abbott Laboratories and Amgen Inc.